Tobacco-Associated Oral Lesions
Tobacco-Associated Oral Lesions
Tobacco-Associated Oral Lesions
LESIONS
A BRIEF PRESENTATION BY
SAMRIDHI SRIVASTAVA
2019-BDS-64
FOURTH YEAR
MRDC
ORAL LESIONS ASSOCIATED WITH
THE USE OF TOBACCO
– Stomatitis Nicotina
– Snuff Dipper Lesion
Mechanical fiction,
Chemical burn,
Candidiasis
TREATMENT
Cessation or reduction of smoking.
LEUKOPLAKIA
Systemic
Genetic
Nutritional deficiency
Idiopathic
2. Axell 1996
1. Homogenous leukoplakia
2. Non homogenous
1. Erythroleukoplakia
2. Nodular
CLINICAL FEATURES
Age :
Middle age & older age, increases with age
>30 years
Peak incidence: >50 years
Sex :
•Male : Female 3:2 (India)
•Male : Female 1:1 (Worldwide)
Phase 2 Thick/ Fissured
/Homogenous
PHASE 1 THIN OR
PRELEUKOPLAKIA
HOMOGENEOUS LESIONS
Papillomatous
Cheek biting
Hyperplastic candidiasis
3.Laboratory investigations
1.Biopsy
CHAIR SIDE INVESTIGATIONS
Conventional
1.VITAL STAINING:
Lugol’s Iodine
Rose bengal staining
Sensitivity: 93.9%
Specificity: 73.7%
2. Exfoliative Cytology:
Class I (Normal): only normal cells observed
Class III (Intermediate): cells display wider atypia that may be suggestive
of cancer, but are not clear-cut, may represent precancerous lesions.
Biopsy is recommended
Class V ( Positive for cancer): cells that are obviously malignant. Biopsy is
mandatory.
34
ADVANCED
ORAL BRUSH BIOPSY
35
Chemiluminisence-
Vizilite
system-Dysplastic cells appear acetowhite
VELscope
36
LABORATORY INVESTIGATIONS
BIOPSY (Gold Standard)
1.Incisional
2.Excisional
3.Punch
HISTOPATHOLOGICAL
FEATURES
Architecture changes
1. Loss of polarity of basal cells
2. The presence of more than one layer of cells having a basaloid
appearance
3. Drop-shaped rete ridges
4. Irregular epithelial stratification
5. Loss of intercellular adherence
6. Keratinization of single cells or cell groups in the prickle cell layer
7. The presence of mitotic figures in the superficial half of the epithelium
Cellular changes
8. Cellular and nuclear pleomorphism
9. Nuclear hyperchromatism
10. Enlarged nuclei
11. Mitotic figures that are abnormal in form
12. Increased number of mitotic figures
13. Increased nuclear- cytoplasmic ratio
Pindborg et al 1997
Classification and Staging System for Oral Leukoplakia
L -SIZE OF THE LEUKOPLAKIA
L1- Size of single or multiple leukoplakia together < 2 cm
L2-Size of single or multiple leukoplakia together 2±4 cm
L3- Size of single or multiple leukoplakia together >4 cm
Lx- Size not specified
P - PATHOLOGY
P0 - No epithelial dysplasia (no or perhaps mild epithelial dysplasia)
P1-Distinct epithelial dysplasia (“mild to moderate'' and moderate to possibly
severe epithelial dysplasia)
Px - Absence or presence of epithelial dysplasia not specified in the pathology
report
STAGING SYSTEM
Stage I - L1P0
Stage II - L2P0
Stage III - L3P0 or L1/L2P1
Stage IV - L3P1
(I. van der Waal, K.P. Schepman, E.H. van der Meij. Oral Oncology 2000; 36: 264-266)
40
TREATMENT
Counseling of the patient for habit cessation
Elimination of risk factors like alcohol and smoking , and advise
Nicotine substitutes.
Medical management:
Carotenoids
o Beta-carotene
o Lycopene
Vitamins
o Vitamin C
o Vitamin E
o Vitamin A
Polyphenols
Bleomycin
Photodynamic therapy
41
Surgical management
Scalpel surgery
Cryosurgery
Laser ablation
Close Follow Up
4 months for the first 2 yrs
6 months until 5yrs
VITAMINS
Vitamin C
RDA 100-200mg/day
Smokers 140mg/day
Vitamin E
800IU/day for 6-9months
Vitamin A
BLEOMYCIN
It is a cytotoxic antibiotic .
Topical bleomycin in treatment of OL is used in dosages of 0.5
% /day for 12 to 15 days or 1% /day for 14 days.
It shows a significant reduction of dysplasia and keratinization.
SURGICAL TREATMENT
Conventional surgery
Cryosurgery : cell death occurs at 20°C. cryoprobe
refrigerated by liquid nitrogen.
Electrocautery : Tissue destruction by high voltage
current.
LASER
MALIGNANT POTENTIAL
Homogenous: 1-7%
Granular/ verruciform: 4-15%
Erythroleukoplakia: 18-47% , 28%
Moderate dysplasia: 4-11%
Severe dysplasia: 20-35%
Floor of mouth: 16- 39%
Ventral surface of tongue: 47%